Stroke Treatment Showdown: Is Combining Therapies Better Than One?
"A new look at how combining intra-arterial thrombolysis (IAT) with mechanical thrombectomy (MT) could change stroke treatment outcomes."
Stroke is a leading cause of disability, and rapid treatment is critical. For many patients suffering from acute ischemic stroke, endovascular interventions, which involve treating the stroke from inside the blood vessels, offer a lifeline.
Among these interventions, mechanical thrombectomy (MT) has become a standard approach, particularly for those ineligible for or unresponsive to intravenous thrombolysis (clot-busting drugs). However, the role of combining MT with intra-arterial thrombolysis (IAT), where clot-busting drugs are delivered directly to the site of the blockage, has remained a topic of investigation.
A retrospective study has shed new light on the potential benefits of this combined approach, comparing outcomes of patients who received MT alone versus those who underwent combined MT and IAT. The results offer valuable insights into improving stroke care and patient recovery.
From Early Trials to Standard Care
The first acute-stroke endovascular device clinical trial, TIME (Thrombectomy in Middle Cerebral Artery Embolism), was launched by Possis Medical using an Angiojet and a modified PROACT-II protocol. It was stopped in 2003 after negative results and was never published; other unsuccessful devices, including lasers, followed. The history of interventional stroke treatment involved varied techniques and materials, and mechanical thrombectomy is now standard care for acute ischemic stroke with large-vessel occlusion.
IAT and MT Combination: A Closer Look at Stroke Treatment
The study, conducted at a comprehensive stroke center, retrospectively reviewed the cases of 200 patients who underwent endovascular treatments for acute ischemic stroke between 2007 and 2011. Out of these, 115 patients met the inclusion criteria for comparison: one group received MT alone, while the other received a combination of MT and IAT. The researchers then analyzed various outcome parameters to assess the safety and efficacy of each approach.
- Discharge NIHSS (National Institutes of Health Stroke Scale): A measure of neurological deficit.
- Clinical improvement: Defined as a decrease of more than 4 points on the NIHSS.
- TIMI 2-3 (Thrombolysis in Myocardial Infarction) flow: Indicating partial to complete recanalization or restoration of blood flow.
- Discharge modified Rankin Scale (mRS) ≤3: Assessing functional independence, with a score of 3 or less indicating a better outcome.
- Symptomatic Intracerebral Hemorrhage (ICH): Bleeding in the brain causing new or worsening neurological symptoms.
- All-cause mortality: Death from any cause.
New Evidence on Bridging Therapy
Bridging therapy combines intravenous thrombolysis with endovascular thrombectomy, but concerns include treatment delays, clot fragmentation or distal migration, and bleeding complications. Thrombolysis may also dissolve distal clots or alter clot properties in ways that could aid retrieval and improve first-pass effect and reperfusion. A 2025 report found that, among patients with large-vessel occlusion treated within 4.5 hours, functional independence at 90 days was higher with intravenous tenecteplase plus thrombectomy than with thrombectomy alone.
Uncertainty, Delays, and Failed Recanalization
Cochrane rates its confidence in evidence on clot-busting medicine before vessel-opening procedures as moderate, citing a wide range of results and differences between studies. A subgroup analysis of the randomized SWIFT-DIRECT trial cautioned that its low power could have missed an important effect; exploratory secondary outcomes suggested a potentially favorable effect of intravenous thrombolysis when in-hospital delays were shorter. Mechanical thrombectomy does not always achieve recanalization: a 2024 retrospective study at a high-volume stroke center identified inadequate thrombus removal and access-route difficulties as common reasons for failure.
Comparing Thrombectomy Alone and Combined Treatment
A randomized-trial meta-analysis reported crude 90-day functional independence rates of 46.0% with endovascular thrombectomy (EVT) alone and 45.5% with intravenous thrombolysis (IVT) plus EVT. In a randomized trial of alteplase before endovascular treatment, mortality was 20.5% with EVT alone and 15.8% with alteplase plus EVT; the adjusted odds ratio was 1.39 (95% CI, 0.84 to 2.30). These figures describe different outcomes, and the mortality estimate's confidence interval is reported alongside the result.
Interpreting the Findings: Risks and Rewards
While the study suggests potential advantages of the combined approach, it also reported higher rates of hemorrhage and slightly increased mortality rates in the combined therapy group. These findings underscore the need for careful patient selection and meticulous execution of the combined technique. Further research, including larger, randomized controlled trials, is essential to validate these findings and refine treatment protocols. In the meantime, this study provides valuable insights for clinicians to consider when making treatment decisions for acute ischemic stroke patients.
Evidence and the Cost of Care
A 2026 systematic review and individual patient data meta-analysis set out to synthesize recent trial evidence on endovascular thrombectomy for patients with extensive ischemic change, including estimates of benefit across clinical and imaging subgroups. Separately, an evidence-based review argued that thrombectomy's potential to reduce immediate and long-term costs should be considered when developing systems of care for acute ischemic stroke. Together, these sources point to the importance of evaluating both treatment benefit in patient subgroups and the wider costs of care.
Evolving Research and Treatment Directions
A 2025 review summarizes current understanding of stroke anatomy, cerebral hypoperfusion, and collateral circulation, and updates evidence from stroke trials and treatments using PRISMA guidelines. Its coverage includes intravenous thrombolysis, endovascular thrombectomy for anterior-circulation stroke, and blood-pressure control after endovascular treatment. A separate 2025 review maps global research trends in mechanical thrombectomy for acute ischemic stroke over the preceding decade.
Recanalization and Care Pathways
A review of thrombolysis and thrombectomy describes ongoing research into more effective treatments, evaluation tools, and efficient care pathways for acute ischemic stroke. It reports an endovascular therapy recanalization rate of about 70–80% and a number needed to treat of 2.6, alongside a low complication rate. These figures frame treatment performance within broader efforts to improve how patients are assessed and cared for.
Real-World Outcomes Beyond the Treatment Window
A 2025 analysis used Oracle Real-World Data, a de-identified multicenter electronic health-record dataset covering January 2016 to January 2023. It compared 3,934 acute ischemic stroke patients who underwent thrombectomy with 3,934 propensity-matched patients who did not. A separate real-world study suggests endovascular treatment beyond six hours was feasible and safe, without increased symptomatic intracranial hemorrhage, among large-vessel-occlusion patients selected using CT perfusion and collateral-circulation assessment.